RESECTISOL IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Resectisol In Plastic Container, and when can generic versions of Resectisol In Plastic Container launch?
Resectisol In Plastic Container is a drug marketed by B Braun and is included in one NDA.
The generic ingredient in RESECTISOL IN PLASTIC CONTAINER is mannitol. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the mannitol profile page.
Summary for RESECTISOL IN PLASTIC CONTAINER
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 176 |
Clinical Trials: | 3 |
Patent Applications: | 4,153 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RESECTISOL IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for RESECTISOL IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/Phase 2 |
National Cancer Institute (NCI) | Phase 1/Phase 2 |
OHSU Knight Cancer Institute | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for RESECTISOL IN PLASTIC CONTAINER
US Patents and Regulatory Information for RESECTISOL IN PLASTIC CONTAINER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B Braun | RESECTISOL IN PLASTIC CONTAINER | mannitol | SOLUTION;IRRIGATION | 016772-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for RESECTISOL IN PLASTIC CONTAINER
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pharmaxis Europe Limited | Bronchitol | mannitol | EMEA/H/C/001252 Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. |
Authorised | no | no | no | 2012-04-13 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |